Where Can I Get Immunotherapy Treatment for Non-Small Cell
- Ganesh Akunoori
- 11 minutes ago
- 13 min read
Introduction
A family member has just been diagnosed with advanced non-small cell lung cancer (NSCLC). The first wave of shock is quickly followed by paralyzing confusion: where do you even begin? Chemotherapy was once the default, but today, the conversation has shifted to immunotherapy.
You've read about it, heard it can be less toxic and more effective for some patients, but the immediate, practical question looms: is it actually available here, and if so, where do you go? In India, NSCLC remains the leading cause of cancer-related mortality worldwide, making urgent, informed action critical.
The good news is that immune checkpoint inhibitors have fundamentally transformed its treatment landscape, and these drugs are accessible, but their availability is heavily concentrated. Getting treatment is a logistical and financial puzzle that you can solve with the right information.
Key Takeaways
Here are the key facts you need before navigating immunotherapy for NSCLC in India:
Approved drugs: The principal agents available are pembrolizumab, nivolumab, and atezolizumab, all targeting the PD-1/PD-L1 pathway.
Biomarker prerequisite: You cannot skip this. A PD-L1 test from a biopsy tissue sample is mandatory to determine if you are a candidate.
Cost per cycle: Budget for ₹1.5 lakh to ₹3 lakh per cycle, a significant recurring expense that demands rigorous financial planning.
Metro-centric availability: Availability is limited to a few tertiary cancer centers, primarily in Mumbai, Delhi, Bangalore, Chennai, and Hyderabad.
Insurance gaps: Do not rely on Ayushman Bharat; it generally excludes immunotherapy. Partial coverage may exist under specific private insurance plans.
Immunotherapy for NSCLC in India: A Definition and Current Landscape
Immunotherapy for lung cancer is not an alternative medicine. It is the use of medicines to help a person's own immune system recognize and destroy cancer cells more effectively. In NSCLC, the most common approach is immune checkpoint inhibition, using drugs that block the PD-1/PD-L1 signaling axis. Cancer cells exploit this receptor to evade T-cells, the body's natural defenders. By blocking this interaction, PD-1 inhibitors like nivolumab (Opdivo) and pembrolizumab (Keytruda), or PD-L1 inhibitors like atezolizumab (Tecentriq), release the brakes on the immune system, allowing a powerful anti-tumor response.
This approach shifts the attack mechanism away from non-specific cytotoxic killing and onto your own immune cells. Chemotherapy acts as a blunt instrument affecting all rapidly dividing cells. Immunotherapy builds lasting immunological memory.
In 2026, real-world adoption of these agents across Indian metros like Mumbai and Hyderabad is strong. Researchers continue investigating resistance mechanisms. KRAS co-mutations with STK11 and KEAP1 are under study to understand why some patients stop responding.
The Central Drugs Standard Control Organization (CDSCO) governs these approvals in India. The original CDSCO imported biologics list from the early 2000s detailed drugs like Rituximab and Trastuzumab for lymphomas and HER2-positive metastatic cancers. The current generation of PD-1 and PD-L1 inhibitors entered the market under later regulatory clearances and are now integrated at various infusion centers.
Approved Immunotherapy Agents: Types, Targets, and Mechanisms
Understanding your specific prescription starts with knowing the agent class. Here are the primary approved and available drugs for NSCLC in India:
Pembrolizumab (Keytruda): A PD-1 inhibitor used first-line as monotherapy when PD-L1 expression is high (Tumor Proportion Score 50% or greater).
Nivolumab (Opdivo): Another PD-1 inhibitor. A recent single-arm phase II study showed that when combined with Stereotactic Body Radiotherapy (SBRT), the median overall survival reached 25.9 months in previously treated advanced NSCLC patients. It can also now be administered as a subcutaneous injection.
Atezolizumab (Tecentriq): A PD-L1 inhibitor that blocks the ligand rather than the receptor. It is commonly used with chemotherapy, irrespective of histology.
Drug Delivery Evolution: Both atezolizumab and nivolumab are available as quick subcutaneous injections administered over several minutes, a practical improvement over traditional hour-long intravenous infusions for some patients.
Top Hospitals and Cancer Centers Offering Immunotherapy for NSCLC in 2026
Your access point is almost certainly a metropolitan city. In Mumbai, Tata Memorial Hospital sets the benchmark for public trust and clinical volume, while P.D. Hinduja Hospital offers it in a private setting.
Delhi’s ecosystem includes the Rajiv Gandhi Cancer Institute and the cancer wing at AIIMS, both equipped with dedicated immuno-oncology tumor boards. In the south, Bangalore's HCG and Apollo hospitals, Chennai’s Cancer Institute (Adyar) and Apollo Proton Centre, and Hyderabad’s centers provide concentrated expertise. For patients specifically in Hyderabad, a specialist like Dr. Bharat Patodiya can coordinate a thorough care plan, helping you understand how this fits into a broader lung cancer treatment strategy.
If you live in a tier-2 city like Nagpur, Jaipur, or Lucknow, you may find an infusion center, but the critical differentiator is the supporting infrastructure. When selecting a center, your checklist must include three non-negotiables: an onsite molecular pathology lab to run and interpret PD-L1 immunohistochemistry (IHC) without external delays, a multidisciplinary tumor board with a medical oncologist specializing in thoracic cancers, and an intensive care unit capable of managing rare but rapid-onset immune-related adverse events.
The Prerequisite: Biomarker Testing as the Gateway to Immunotherapy
Do not start immunotherapy until these diagnostic steps are complete. The entire treatment plan depends on a piece of tissue from your biopsy:
Obtain a tissue biopsy: A core needle biopsy or excisional biopsy provides the sample needed. Cytology from fine-needle aspiration is often insufficient.
Request PD-L1 IHC testing: The pathologist stains the tissue for PD-L1 and calculates the Tumor Proportion Score (TPS). This percentage tells your oncologist the likelihood of a strong response. A high TPS often means monotherapy is a practical option.
Perform thorough genomic profiling: In non-squamous NSCLC, test for actionable driver mutations, particularly EGFR and ALK. This prevents giving immunotherapy to an EGFR-mutant patient where it is typically ineffective. That patient needs a targeted pill like osimertinib instead.
Calculate turnaround time: Expect roughly 10 to 14 days for the complete molecular profile. It is a necessary wait before the first infusion can be scheduled.
The True Cost of Immunotherapy in India: A Detailed INR Breakdown
The numbers are large, and they repeat every two to three weeks. The table below shows per-cycle costs for the three main agents available in 2026:
Cost Dimension | Pembrolizumab (Keytruda) | Nivolumab (Opdivo) | Atezolizumab (Tecentriq) |
Drug Cost per Cycle (approx.) | ₹2.5 lakh to ₹3 lakh | ₹1.5 lakh to ₹2 lakh | ₹1.5 lakh to ₹2.5 lakh |
Administration & Daycare Fees | ₹10,000 to ₹25,000 | ₹10,000 to ₹25,000 | ₹10,000 to ₹25,000 |
Common Dosing Schedule | Every 3 weeks (200mg or 400mg every 6 weeks) | Every 2 weeks (240mg) or 4 weeks (480mg) | Every 3 weeks (1200mg) |
Projected Annual Cost (Drug Only) | ₹40 lakh, ₹50 lakh | ₹35 lakh, ₹45 lakh | ₹35 lakh, ₹50 lakh |
Oncologists typically plan for a fixed duration of 2 years of continuous therapy for patients who are responding and tolerating the drug, or until disease progression. New biosimilar entries are beginning to exert slight downward pressure on nivolumab pricing in 2026. Do not expect a dramatic drop from the innovator brands in the immediate future.
Insurance and Financial Support: Bridging the Accessibility Gap
Assume Ayushman Bharat will not cover it. While this government scheme covers generic chemotherapy, it generally excludes high-cost immunotherapy.
Private insurance offers partial protection. If you hold a corporate policy or a high-value individual plan, check for a specific oncology rider. The standard room-rent capping model often fails with daycare infusions. Your policy must explicitly state coverage for immunotherapy drugs, OPD-based procedures, and consumables. Without those three line items, a daycare infusion bill can land entirely in your lap.
Many policies still define hospitalisation by a 24-hour admission rule. A 90-minute infusion followed by observation does not meet that definition. Call your insurer before the first cycle. Ask them to confirm coverage in writing and flag any sub-limits on modern cancer drugs.
If your policy falls short, some manufacturers in India run patient access programmes that bring down the monthly outlay. These are time-bound and income-linked. A hospital's financial counsellor can tell you which programmes are active for your prescribed drug.
Manufacturer helplines are the other direct route. Both are worth a call before you assume the full sticker price is final. Crowdfunding fills a last-mile gap but it demands a sprint.
Platforms that verify medical need convert better than generic fundraisers. A clear treatment summary, a hospital letterhead estimate, and a short video update every week tend to sustain contributions. The difference between a campaign that stalls at ₹30,000 and one that covers two cycles often comes down to how regularly you post proof of spend.
Tax relief under Section 80DDB exists for specified diseases, including malignant cancers. The deduction cap sits at ₹75,000 for individuals below 60 and ₹1,00,000 for senior citizens.
Save every infusion pharmacy receipt, every diagnostic invoice, and the discharge summary. An annual folder of those documents turns a tax-time scramble into a two-hour filing.
How to Start Treatment: A Step-by-Step Process from Diagnosis to Infusion
Your first real step is a biopsy that does more than confirm cancer, it maps the tumor's molecular ID. The tissue sample is tested for PD-L1 expression levels, a protein that acts like a shield hiding cancer from your immune system. If your NSCLC is non-squamous, your oncologist also orders genomic profiling to look for driver mutations in genes like EGFR, ALK, or ROS1.
This testing is non-negotiable. Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have fundamentally transformed its treatment landscape, but the therapy only works predictably when the tumor shows sufficient PD-L1 expression. Without these results, no responsible oncologist starts immunotherapy.
A multidisciplinary tumor board then reviews your case. Think of it as a room where your pulmonologist, medical oncologist, radiation oncologist, and pathologist debate the staging, biomarkers, and your overall health. They settle on a protocol based on the evidence and your body's specifics.
If immunotherapy with an agent like pembrolizumab (Keytruda) or nivolumab (Opdivo) fits, the decision moves to insurance clearance. This is where reality bites in India. A single cycle costs ₹1.5 lakh to ₹3 lakh.
Private insurers often cover a portion, but Ayushman Bharat categorically excludes it for NSCLC. Be prepared for a financial authorization window that can take a week or more.
Once cleared, the infusion itself is typically scheduled within two to four weeks of the positive marker report. You sit in a dedicated infusion bay, and the drug drips intravenously over 30 to 90 minutes, though newer formulations of atezolizumab and nivolumab can also be given as a subcutaneous injection over several minutes. The first session includes close monitoring for infusion reactions, fever, chills, dizziness, or trouble breathing.
These are not common, but the team watches for them. After the first dose, you cycle back every two to four weeks, typically for months. Regular scans then check whether the T-cells are actually biting into the tumor.
Choosing Your Path: Immunotherapy vs. Chemotherapy vs. Targeted Therapy
You are not choosing between good, better, and best. You are matching the right weapon to the tumor’s biology, and each option comes with a specific price tag and access map in India. Chemotherapy remains the blunt default with zero biomarker requirement: it kills rapidly dividing cells and costs ₹10,000 to ₹30,000 per cycle, with full Ayushman Bharat coverage. You can get it in a district hospital.
Targeted therapy, in contrast, is a sniper. It demands a confirmed driver mutation like EGFR or ALK and uses oral pills like osimertinib around ₹1 lakh to ₹2.5 lakh a month. If your tumor carries that mutation, targeted agents often outperform everything else with manageable side effects, but mutations are present only in a subset of non-squamous patients.
Immunotherapy sits in the middle of complexity and cost. It unleashes your T-cells against the cancer by blocking the PD-1/PD-L1 checkpoint. The required testing, PD-L1 immunohistochemistry, is now standard in tertiary centers in Mumbai, Delhi, Bangalore, and Chennai, but availability in tier-2 and tier-3 cities is very limited.
You will likely travel for it. The financial strain is real: at ₹1.5 lakh to ₹3 lakh per cycle, a six-month course can exhaust most families’ savings.
However, when it works in a high PD-L1 expresser, the response can be durable for years, not months. This is the payoff that justifies the logistics.
The hard truth is that chemotherapy still works everywhere and immunotherapy doesn't. If PD-L1 is low or absent, adding immunotherapy to chemotherapy often yields a better result than either alone, a strategy studied in trials like CheckMate 227. Your choice thus collapses into a single question for your oncologist: Does my tumor’s molecular profile justify moving away from standard chemotherapy, and can our finances absorb the gap that insurance won't cover? The answer lives in the biopsy report, not in hope. For a detailed consultation on integrating these options, a specialist like Dr. Bharat Patodiya in Hyderabad can run the specific molecular analysis and plot the real-world cost trajectory before you commit to a line of therapy.
8. Insurance & Financial Assistance
Most immunotherapy treatments in India are not covered by government health schemes. Several private insurers now sell cancer-specific riders that reimburse a portion of the bill. Ask your provider directly about daycare procedure coverage because infusions rarely require an overnight stay, and that classification determines whether the claim is approved.
Pharmaceutical patient assistance programs have become a critical lifeline. The Merck Foundation (pembrolizumab) and the Tata Memorial Centre offer income-based subsidies that can cut out-of-pocket costs by 40 to 60 percent. To qualify, you typically need income certificates, prescriptions from registered oncologists, and a detailed treatment plan.
Charitable trusts fill the gaps that insurance and pharma programs leave behind. Organizations like the Cipla Foundation and Caring for Life award grants based on financial need. Start early. Foundation reviews go through a committee, and that alone can push scheduling out by weeks. A specialist like Dr. Bharat Patodiya and the social work teams at major cancer centers can handle the paperwork for multiple aid applications at the same time.
9. The Treatment Timeline: From Suspected Diagnosis to First Infusion
Getting from a suspicious chest X-ray to your first immunotherapy infusion follows a standardized medical workflow. Understanding this pathway eliminates surprises.
After imaging reveals a mass, you'll undergo a CT-guided biopsy. The key moment is your oncologist's order for PD-L1 IHC testing on the tissue block. Expect results in 7 to 10 working days. Once the biopsy confirms NSCLC and the PD-L1 TPS is known, your case proceeds to the multidisciplinary tumor board where medical and radiation oncologists align on a final recommendation.
With a recommendation for immunotherapy in hand, the pre-infusion logistics kick in. If your veins are difficult or multiple cycles are planned, a port-a-cath is placed surgically. A pre-treatment lab panel confirms organ function, and then you sit for the first infusion, a process typically initiated within 2 to 4 weeks of the positive biomarker result. A typical cycle for agents like pembrolizumab might run 30 minutes for the drip, followed by an observation period, and then you go home.
10. Comparing Treatment Paths: Immunotherapy vs. Targeted Therapy vs. Chemotherapy
Your oncologist draws a treatment path based on your tumor's genetic identity card. The key clinical differentiator is the biomarker report.
Treatment Class | Mechanism of Action | Primary Candidate Biomarker | Key Agents Available in India | Approximate Cost Per Cycle (Drug Only) | Ayushman Bharat Coverage |
Immunotherapy (IO) | Immune checkpoint inhibition (PD-1/PD-L1 axis) | PD-L1 TPS ≥ 50% (or ≥ 1% for chemo-IO) | Pembrolizumab, Nivolumab, Atezolizumab | ₹1.5 Lakh, ₹3 Lakh | Generally Excluded |
Targeted Therapy (TT) | Tyrosine kinase inhibition of driver mutations | EGFR exon 19 del, L858R; ALK fusion; ROS1 fusion | Osimertinib, Crizotinib, Alectinib | ₹1 Lakh, ₹2.5 Lakh (varies widely by agent generation) | Rarely Covered |
Chemotherapy (Chemo) | Cytotoxic cell kill (non-specific, rapidly dividing) | None (empiric histology: squamous vs. non-squamous) | Pemetrexed, Cisplatin, Carboplatin, Paclitaxel | ₹10,000, ₹30,000 | Included (Limited formulary) |
If you have an EGFR activating mutation, targeted therapy is the standard of care. Immunotherapy in this context can be ineffective and potentially harmful when used first-line. Conversely, if you have high PD-L1 (≥50%) and no actionable driver mutation, monotherapy with pembrolizumab could offer a longer, chemotherapy-free quality of life. For patients who do not fit these binaries, the data supports combining chemotherapy with immunotherapy, a strategy that often improves outcomes regardless of moderate PD-L1 expression levels.
This complex logic is why treatment rests entirely on a thorough biopsy. Making the correct first-line choice determines both survival and the quality of the months that follow.
Conclusion
Immunotherapy for NSCLC in India is accessible today, but it demands a clear-eyed view of the ground rules: the treatment only works when the right biomarkers light up, most centers that deliver it sit in the metro cities, and a course still puts real pressure on a family's finances.
Your first move is the biomarker report. Get the PD-L1 and molecular profiling done before anyone hands you a treatment plan. Walk away if a doctor skips this step.
Your second move is the money. Stack what you can: a critical-illness rider on your policy, a pharma access program that covers part of the drug cost, and a line-by-line estimate from the hospital's billing desk. Blunt budgeting at the start prevents hard conversations two cycles in.
The drugs are here and the clinicians who know how to use them are here. What decides whether you reach the infusion chair is the paperwork and planning you lock down first.
Frequently Asked Questions
What are the top hospitals in India for NSCLC immunotherapy in 2026?
The premier centers in India each offer dedicated immuno-oncology teams and on-site biomarker labs:
Mumbai: Tata Memorial Hospital
Delhi: AIIMS and Rajiv Gandhi Cancer Institute
Bangalore: HCG and Apollo hospitals
Chennai: Cancer Institute Adyar and Apollo Proton Centre
Hyderabad: Continental and Yashoda Hospitals
What is the total monthly cost of immunotherapy for lung cancer in India, and does Ayushman Bharat cover it?
Immunotherapy costs between ₹1.5 lakh and ₹3 lakh per cycle, typically administered every 3 or 4 weeks. A full year can range from ₹40 lakh to ₹50 lakh. Ayushman Bharat does not cover these drugs, though it pays for standard chemotherapy. Financial relief comes only from private insurance oncology riders or pharmaceutical patient assistance programs like the one linked to pembrolizumab.
Which immunotherapy drugs are approved and accessible for NSCLC in India?
The CDSCO regulates and permits pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq) for NSCLC. Pembrolizumab is a PD-1 inhibitor, frequently used as a first-line monotherapy in high PD-L1 expressors. Nivolumab also targets PD-1 and shows efficacy, while atezolizumab inhibits the PD-L1 ligand and is often paired with chemotherapy.
Is immunotherapy for lung cancer available in cities like Patna, Nagpur, or Bhopal?
Routine availability in tier-2 cities is highly limited. While a few infusion centers may exist in state capitals, the required support infrastructure (molecular pathology labs for PD-L1 testing, immunotherapy-experienced ICU teams, subspecialty medical oncologists) is concentrated almost exclusively in the metros.
How long does it take to start immunotherapy after a lung cancer diagnosis?
Plan for a 2 to 4-week initiation window after the biopsy. The timeline includes 10 to 14 days for PD-L1 and genomic testing, followed by multidisciplinary board review, financial clearance, and port-a-cath placement if needed. Any attempt to rush treatment without the biomarker results is dangerous and could lead to ineffective, costly care.
Sources
#1 Lung Cancer Specialist (Hyderabad) | Dr. Bharat Patodiya - www.drbharatpatodiya.com
Integrative Lung Cancer Treatment Options: Complete 2026 Guide to Comprehensive Care - www.drbharatpatodiya.com
9 Most Affordable Lung Cancer Treatment Centers in India - www.drbharatpatodiya.com
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy - PMC - pmc.ncbi.nlm.nih.gov
Current and future immunotherapies for NSCLC - PubMed - pubmed.ncbi.nlm.nih.gov
SBRT plus nivolumab in advanced NSCLC: a phase II multicenter study with exploratory bone metastases subgroup analysis - ScienceDirect - www.sciencedirect.com
UCSF Non-Small Cell Lung Cancer Clinical Trials for 2026 — San Francisco Bay Area - clinicaltrials.ucsf.edu
Pembrolizumab - www.cancer.org
Comments